General Motors, Abbott Laboratories a Johnson & Johnson zvýšily výhled a po zveřejnění výsledků posílily. U JNJ to znamená i cestu k více než 100 miliardám USD ročních tržeb v roce 2026.
Key Takeaways JNJ, ABT, and GM have all recently raised guidance. Each has seen post-earnings strength, with near-term momentum supported by the updated outlooks. Guidance upgrades are a solid indicator of fundamental business strength. The 2026 Q2 earnings season will continue at a rapid pace in the coming weeks, with many notable companies on the reporting docket. The big banks helped kick the period off positively, though post-earnings reactions haven’t been great for all that have reported.
But General Motors (GM - Free Report) , Abbott Laboratories (ABT - Free Report) , and Johnson & Johnson (JNJ - Free Report) have been nice standouts so far, all raising guidance and seeing strength post-earnings.
Guidance upgrades are generally one of the most bullish things to watch for in earnings season, as renewed outlooks can often lead to positive EPS revisions, the strongest driver of a stock’s near-term movement.
General Motors Raises AgainGeneral Motors posted a double-beat relative to our consensus expectations, with EPS reflecting a positive surprise of 14%. Sales of $48.0 billion came in 3% above our consensus sales estimate.
The company raised its full-year 2026 EBIT adjusted guidance for the second time this year, with adjusted EPS guidance also getting raised. And for the cherry on top, it also lifted its automotive operating cash flow outlook, overall reflecting a rock-solid release.
EPS revisions for its current fiscal year got an additional boost from the lifted outlook, with the trend overall remaining positive for the entire last year. The profitability picture of automotive players is always the key driver behind sentiment, and the updated guidance across key profitability metrics remains a huge positive for GM’s share momentum overall.
Image Source: Zacks Investment Research
Abbott Laboratories Bounces BackAbbott Laboratories similarly posted a double-beat relative to our consensus expectations, with adjusted EPS of $1.31 reflecting a 2.3% beat while sales of $12.6 billion came in roughly 1% ahead of expectations.
The company lifted its adjusted EPS guidance to $5.45-$5.60, modestly higher than the previous $5.38-$5.58 per share range. It also reaffirmed its current-year comparable sales guidance, now expecting accelerating revenue and earnings growth in the second half of the year.
The stock has had a rough YTD performance overall, but the release has helped keep momentum going in a positive direction. Importantly, it reflects the first instance of the stock seeing positive gains over the last four quarters.
The EPS revisions picture for its current fiscal year has finally started to show positive momentum following the release, with the more recent revisions definitely holding more weight from a near-term perspective. Continued positivity on the revisions front will support further share momentum, with the current 17.3X forward 12-month earnings multiple trading at a significant discount to the 23.3X five-year median.
Image Source: Zacks Investment Research
Johnson & Johnson Keeps Cruising Johnson & Johnson beat on both the top and bottom line in its recent release, continuing a streak of earnings excellence. In fact, the company has posted a double-beat in nine consecutive quarters.
Strong operational performance led the company to increase both its current fiscal year sales and adjusted EPS guidance, with JNJ now on track to meet its 2026 target of more than $100 billion in annual revenue for the first time in its history.
EPS revisions for its current fiscal year have followed the upgrade, continuing the bullish trend established over the past year. The stock overall reflects a highly defensive investment given its consistent revenue-generating nature throughout many economic cycles.
Image Source: Zacks Investment Research
Bottom Line
Guidance upgrades are always a bullish development to watch for in earnings releases, commonly leading to positive post-earnings share reactions. While it isn’t a guarantee that a stock will pop just because it raised its outlook, it still remains a favorable factor from a fundamental standpoint. Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors.
All three stocks above - General Motors (GM - Free Report) , Abbott Laboratories (ABT - Free Report) , and Johnson & Johnson (JNJ - Free Report) – have recently upped their outlooks. While they may not be as flashy as high-flying tech stocks amid the AI craze, their improving business fundamentals can’t be overlooked.
Intuitive Surgical ve 2. čtvrtletí zvýšila počet výkonů o 16 % a rozšířila instalovanou základnu na téměř 13 000 systémů po celém světě. Abbott rostl napříč více segmenty, ale jeho růst je méně soustředěný.
Key Takeaways ISRG is favored for its expanding robotic surgery ecosystem and stronger long-term growth outlook.Intuitive Surgical grew procedures, expanded its installed base and advanced da Vinci 5, SP and Ion.Abbott posted broad-based growth across devices, diagnostics, diabetes care and nutrition. Despite sharp declines in 2026, Intuitive Surgical (ISRG - Free Report) and Abbott Laboratories (ABT - Free Report) remain among the highest-quality names in MedTech. ISRG has declined 32.1% year to date, while ABT is down 20.1%, though both continue to execute well in their core businesses.
Intuitive Surgical’s growth is being fueled by the expanding adoption of its robotic surgery ecosystem, including da Vinci 5, SP and Ion platforms, while Abbott is benefiting from balanced momentum across cardiovascular devices, diagnostics, diabetes care and nutrition.
Looking ahead, both companies expect growth to continue through 2026, although Intuitive Surgical’s expanding robotic surgery franchise and innovation pipeline position it for stronger long-term upside.
YTD Price Chart ISRG vs ABT
Image Source: Zacks Investment Research
Case for ISRGIntuitive Surgical continues to widen its competitive moat by building a comprehensive robotic-assisted surgery ecosystem rather than relying on a single platform. During the second quarter, total procedures increased 16%, supported by 15% growth in da Vinci procedures and an impressive 36% increase in Ion procedures.
Adoption remained strong across da Vinci 5, single-port (SP) systems and Ion, while the company expanded its installed base to nearly 13,000 systems globally. Continued upgrades to da Vinci 5, broader adoption of XiR in ambulatory surgery centers and cost-sensitive international markets, and ongoing investments in AI-enabled workflow, simulation and telepresence reinforce management's long-term growth strategy.
Growth opportunities extend well beyond traditional robotic surgery. SP procedures surged 61%, Ion procedures surpassed 400,000 cumulatively, and management continues to invest in new disease areas such as gastrointestinal robotics, cardiac surgery and nipple-sparing mastectomy. Programs designed to reduce customer costs, including the upcoming EndoWrist extended-use initiative, should further expand adoption across outpatient procedures and international markets.
The company also faces several challenges, including slower U.S. elective procedure growth tied to changing patient coverage dynamics, competitive pressure in China, GLP-1-related weakness in bariatric surgery and higher R&D spending. Nevertheless, Intuitive Surgical continues to guide toward healthy procedure growth for 2026 while investing aggressively to extend its technology leadership.
ISRG’s Sales & EPS Growth Estimate
Image Source: Zacks Investment Research
Case for ABTAbbott's growth strategy is built on diversification across multiple healthcare markets rather than dependence on any single business. Medical Devices remained a key contributor in the second quarter, with 8.5% growth driven by electrophysiology, rhythm management, heart failure and continuous glucose monitoring. Management expects growth to accelerate further as Volt 2.0, TactiFlex Duo, Libre Duo, Amulet 360 and several cardiovascular products are commercialized over the coming year. Strong momentum in diagnostics, emerging-market pharmaceuticals and improving nutrition performance also support ABT’s balanced growth outlook.
Abbott's broad portfolio provides resilience, but it also means growth is spread across numerous franchises rather than being driven by a single transformational platform. While continuous glucose monitoring remains a significant long-term opportunity, management acknowledged that reimbursement expansion timing remains difficult to predict.
Cancer diagnostics, core laboratory testing and electrophysiology are expected to drive second-half acceleration, while nutrition continues recovering steadily. Risks include declining respiratory testing volumes, reimbursement uncertainties for diabetes products and the need to execute multiple product launches successfully to sustain projected acceleration. Overall, Abbott's diversified model provides stability but offers a less concentrated growth story than Intuitive Surgical's robotics franchise.
ABT’s Sales & EPS Growth Estimate
Image Source: Zacks Investment Research
Valuation ComparisonDespite a steep fall in its valuation since the beginning of 2025, ISRG trades at a premium, supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 30.55, above the industry average of 24.41, and carries a Value Score of D.
ISRG’s P/E F12M Chart
Image Source: Zacks Investment Research
ABT offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 17.33X, slightly above the industry average of 16.02X. ABT carries a Value Score of C.
ABT’s P/E F12M Chart
Image Source: Zacks Investment Research
ConclusionBoth companies possess durable competitive advantages and robust innovation pipelines. Abbott offers investors diversified exposure across diagnostics, cardiovascular devices, diabetes care and nutrition, helping reduce reliance on any single market. Intuitive Surgical stands out for its leadership in robotic-assisted surgery, expanding clinical indications, accelerating adoption of da Vinci 5, SP and Ion, and sustained investment in next-generation technologies. Although ISRG trades at a premium valuation, its stronger innovation pipeline, faster-growing robotic ecosystem and Zacks Rank #2 (Buy) make it a more compelling long-term MedTech investment than Abbott, which carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Andra AP fond v 1. čtvrtletí snížil podíl v Abbott Laboratories o 36,4 % na 206 708 akcií v hodnotě 21,223 milionu USD. Abbott zároveň oznámil tržby 12,51 miliardy USD a EPS 1,31 USD, nad odhady.
Andra AP fonden lowered its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 36.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 206,708 shares of the healthcare product maker’s stock after selling 118,500 shares during the quarter. Andra AP fonden’s holdings in Abbott Laboratories were worth $21,223,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the stock. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the fourth quarter worth approximately $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the fourth quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.
Analysts Set New Price Targets ABT has been the subject of several recent analyst reports. Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Piper Sandler reissued an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.61.
View Our Latest Stock Report on ABT
Abbott Laboratories Trading Up 1.0% NYSE:ABT opened at $101.72 on Tuesday. The stock has a market cap of $177.18 billion, a price-to-earnings ratio of 32.92, a PEG ratio of 1.73 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average price is $90.28 and its 200-day moving average price is $101.84. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is 81.55%.
Insider Transactions at Abbott Laboratories In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.
Abbott Laboratories Company Profile (Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles Five stocks we like better than Abbott Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAssetmark Inc. Has $9.79 Million Stock Position in Spotify Technology $SPOT
NEXT HEADLINE »Baader Bank Aktiengesellschaft Trims Stock Holdings in Walmart Inc. $WMT
AlTi Global snížila v 1. čtvrtletí podíl v Abbott Laboratories o 54,7 % a prodala 12 779 akcií. Po transakci držela 10 563 akcií v hodnotě 1,085 mil. USD.
AlTi Global Inc. lowered its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 54.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,563 shares of the healthcare product maker’s stock after selling 12,779 shares during the period. AlTi Global Inc.’s holdings in Abbott Laboratories were worth $1,085,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes A number of equities analysts have weighed in on the company. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday, April 22nd. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.61.
Read Our Latest Report on Abbott Laboratories
Insiders Place Their Bets In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.
Abbott Laboratories Stock Up 1.0% Shares of ABT opened at $101.72 on Tuesday. The company’s 50-day moving average price is $90.28 and its 200 day moving average price is $101.84. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $177.18 billion, a P/E ratio of 32.92, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.
Abbott Laboratories Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is presently 81.55%.
Abbott Laboratories Profile (Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles Five stocks we like better than Abbott Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
Allspring Global Investments Holdings zvýšil ve 1. čtvrtletí podíl v Abbott Laboratories o 11,9 % na 468 676 akcií. Abbott zároveň oznámil EPS 1,31 USD a výnosy 12,51 miliardy USD, obojí nad odhady.
Allspring Global Investments Holdings LLC raised its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 11.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 468,676 shares of the healthcare product maker’s stock after acquiring an additional 50,017 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Abbott Laboratories were worth $47,983,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. One Day In July LLC boosted its holdings in Abbott Laboratories by 3.6% in the first quarter. One Day In July LLC now owns 3,669 shares of the healthcare product maker’s stock worth $377,000 after purchasing an additional 127 shares during the last quarter. Independent Financial Group LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter worth $1,545,000. Frazier Financial Advisors LLC boosted its stake in shares of Abbott Laboratories by 7.8% in the 1st quarter. Frazier Financial Advisors LLC now owns 28,864 shares of the healthcare product maker’s stock worth $2,964,000 after buying an additional 2,089 shares during the last quarter. D.A. Davidson & CO. grew its holdings in shares of Abbott Laboratories by 2.5% in the first quarter. D.A. Davidson & CO. now owns 186,786 shares of the healthcare product maker’s stock worth $19,177,000 after acquiring an additional 4,553 shares during the period. Finally, Beaumont Financial Advisors LLC increased its position in Abbott Laboratories by 193.8% during the first quarter. Beaumont Financial Advisors LLC now owns 69,183 shares of the healthcare product maker’s stock valued at $7,103,000 after acquiring an additional 45,634 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Price Performance NYSE:ABT opened at $100.71 on Friday. The business’s 50-day simple moving average is $89.89 and its two-hundred day simple moving average is $102.17. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock has a market cap of $175.41 billion, a PE ratio of 32.59, a P/E/G ratio of 1.73 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.
Abbott Laboratories Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.
Trending Headlines about Abbott Laboratories Here are the key news stories impacting Abbott Laboratories this week:
Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results Insider Activity In related news, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.
Wall Street Analyst Weigh In Several equities research analysts have recently commented on ABT shares. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research report on Wednesday, April 22nd. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus reduced their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Oppenheimer decreased their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.61.
View Our Latest Report on Abbott Laboratories
Abbott Laboratories Profile (Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Recommended Stories Five stocks we like better than Abbott Laboratories Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAMG National Trust Bank Grows Position in JPMorgan Chase & Co. $JPM
NEXT HEADLINE »Concordia Financial Group (OTCMKTS:CCRDF) Director Purchases $1,003,436.10 in Stock
Abbott Laboratories oznámila za 2. čtvrtletí EPS 1,31 USD, nad odhadem 1,28 USD, a zvýšila výhled upraveného EPS za fiskální rok 2026 na 5,45–5,60 USD.
Assetmark Inc. grew its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 8.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 202,552 shares of the healthcare product maker’s stock after purchasing an additional 16,506 shares during the period. Assetmark Inc.’s holdings in Abbott Laboratories were worth $20,796,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Wall Street Analyst Weigh In ABT has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Leerink Partners lowered their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a report on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.61.
View Our Latest Stock Report on ABT
Abbott Laboratories Trading Up 1.9% Abbott Laboratories stock opened at $100.71 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The business’s fifty day moving average is $89.89 and its 200 day moving average is $102.17. The stock has a market capitalization of $175.41 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.
Abbott Laboratories Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is 70.59%.
Key Abbott Laboratories News Here are the key news stories impacting Abbott Laboratories this week:
Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results Insider Activity at Abbott Laboratories In other news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.
Abbott Laboratories Profile (Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Read More Five stocks we like better than Abbott Laboratories Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEGilead Sciences, Inc. $GILD Shares Sold by Allspring Global Investments Holdings LLC
Abbott vyšetřuje dva kybernetické incidenty s neoprávněným přístupem do některých interních systémů v části onkologické diagnostiky a do portálu LabCentral. Firma uvedla, že její provoz nebyl zasažen a nečeká materiální dopad na byznys ani finanční výsledky.
A logo of Abbott at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab
CompaniesJuly 17 (Reuters) - Abbott Laboratories (ABT.N), opens new tab is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and its LabCentral portal, the company said on Friday, adding that its operations were not affected.
No other businesses, sites or systems were impacted by the incident at the cancer diagnostics unit, the medical device maker said, adding that legacy Exact Sciences systems were separate from Abbott's systems.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
A hacker also allegedly gained access to the LabCentral portal, an externally facing third-party-hosted portal used by Abbott's core laboratory diagnostics business. But there had been no impact to its businesses or customers and no known exposure of sensitive customer or business information, the company said.
Cyberattacks have increasingly targeted healthcare companies, with recent incidents affecting firms such as Clover Health Investments (CLOV.O), opens new tab, Stryker (SYK.N), opens new tab, Medtronic (MDT.N), opens new tab, Novo Nordisk (NOVOb.CO), opens new tab and West Pharmaceutical Services (WST.N), opens new tab.
Such incidents can disrupt operations, impact access to data and add to concerns about safeguarding sensitive information.
LabCentral contained publicly available technical product reference documents, including operating manuals, troubleshooting checklists and product specifications, and did not contain proprietary or sensitive customer or business information, Abbott said.
The company added it had taken steps to address the matter, engaged outside cybersecurity experts and law enforcement, and was continuing to investigate what information may have been accessed.
Abbott does not expect any material impact on its business or financial results from the incidents.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Abbott Laboratories ve 2. čtvrtletí zvýšil srovnatelný prodej o 4,8 % a upravený EPS na 1,31 USD. Zároveň zvedl celoroční výhled upraveného EPS na 5,45 až 5,60 USD.
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetAbbott Laboratories NYSE: ABT reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters.
The company reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5% and raised its adjusted EPS guidance range to $5.45 to $5.60. Chief Financial Officer Phil Boudreau said Abbott expects third-quarter adjusted EPS of $1.38 to $1.46.
Get Abbott Laboratories alerts:
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?Ford said Abbott entered the second half of the year with “momentum building across the portfolio” and “clear line of sight” to the drivers behind expected sales growth acceleration. He said the company’s focus on gross margin expansion supported the higher earnings outlook.
Margins Improve as Sales Growth Accelerates Boudreau said second-quarter adjusted gross margin was 58.0% of sales, up 100 basis points from the prior year. He attributed the improvement to favorable business mix within Abbott’s legacy portfolio, the addition of Exact Sciences, operational improvements and disciplined execution of margin expansion initiatives.
Abbott Stock Crash: Rebound Could Be Coming FastAdjusted research and development expense was 6.9% of sales, while adjusted selling, general and administrative expense was 28.6% of sales. Foreign exchange had a favorable 0.8% year-over-year impact on second-quarter sales, slightly better than Abbott expected in April. Based on current rates, Boudreau said the company expects foreign exchange to have a positive impact of about 1% on full-year sales, including an expected negative impact of about 1% in the third quarter.
Diagnostics and Nutrition Show Mixed Trends In diagnostics, Ford said Abbott’s core laboratory business reflected strong demand for testing, which he described as a useful indicator of broader healthcare activity. U.S. core laboratory sales grew 7.5%, and Ford said the company continued to post strong performance in Latin America. During the question-and-answer session, he said hospital lab testing within Abbott’s U.S. core lab business was up 13% in the quarter.
Rapid and molecular diagnostics sales declined 8%, driven by an expected drop in respiratory virus testing following a weaker-than-normal season that ended during the quarter.
Cancer diagnostics sales grew 13%, supported by mid-teens growth in Cologuard, contributions from precision oncology and international growth. Ford said Abbott continues to expect cancer diagnostics growth in the second half to exceed first-half growth, helped by care gap programs, recently launched tests and international adoption. He also noted that the American Cancer Society updated its colorectal cancer screening guidelines in May, reaffirming Cologuard and Cologuard Plus as preferred screening options.
Nutrition sales came in slightly ahead of Abbott’s expectations for the second straight quarter, according to Ford. Sales increased sequentially by $125 million, supported by improving trends in both pediatric and adult nutrition. International pediatric nutrition returned to positive growth, rising 6.5% in the quarter. In the U.S. pediatric business, Ford said Abbott exited the quarter with the full benefit of recent WIC contract wins in its run rate and is now the market leader in both WIC and non-WIC segments.
In adult nutrition, Ford said the company continued to see positive volume trends after price actions taken late last year. U.S. retail consumption of Ensure rose by double digits compared with levels exiting last year. Abbott is also seeing contributions from new versions of Ensure featuring higher protein, lower sugar and updated labeling and packaging.
Medical Devices Growth Led by EP, Rhythm Management and Diabetes Care Medical devices sales grew 8.5%, with Abbott’s cardiovascular device portfolio also up 8.5%. Ford said growth was led by low-teens growth in electrophysiology and high-single-digit growth in rhythm management and heart failure.
In electrophysiology, Ford said the second quarter marked the beginning of an acceleration in the business. Abbott launched its next-generation Volt pulsed field ablation catheter, commonly called Volt 2.0, in the U.S. in May and expects to move from limited market release to full market release in the third quarter. Internationally, the rollout of Volt and TactiFlex Duo is gaining traction, with growth of more than 20% in Europe.
Rhythm management sales grew 9.5%, supported by expanded use of the AVEIR pacemaker across single- and dual-chamber segments and broader international adoption. Heart failure sales grew 9%, led by double-digit growth in the U.S. from Abbott’s heart assist devices.
In diabetes care, continuous glucose monitoring sales exceeded $2 billion and grew 9.5%. Abbott received CE mark in May for Libre Duo, which Ford described as the world’s first dual glucose-ketone wearable sensor. The company plans to begin the international rollout in the fall and bring the product to the U.S. after FDA approval.
Pipeline Updates Include New Launches and Clinical Trials Ford highlighted several pipeline milestones, including completion of patient enrollment in the TECTONIC coronary intravascular lithotripsy pivotal trial and completion of Abbott’s FDA submission for approval of its new Amulet 360 left atrial appendage device.
He said Abbott expects to launch Amulet 360, Libre Duo, its coronary IVL product and TactiFlex Duo PFA catheter in the U.S. over the next 12 months. The company also remains on track to begin patient enrollment in the fourth quarter for several clinical trials, including studies for a balloon-expandable TAVR valve, a leadless conduction system pacing device using the AVEIR platform, a mitral replacement valve developed after Abbott’s acquisition of Cephea Valve Technologies, a peripheral IVL device developed after the acquisition of CSI and a wearable continuous lactate monitoring sensor intended to reduce sepsis risk after hospital discharge.
Management Addresses Demand, CGM Reimbursement and 2027 Setup During the call’s Q&A session, Ford said Abbott is not seeing signs of weakening procedure volumes in its businesses, despite investor concerns tied to hospital-sector preannouncements and possible Medicaid disenrollment. He said Medicare, not Medicaid, is the larger payer for many medical device procedures, including more than two-thirds of Abbott’s U.S. cardiovascular business. He also said demand for high-acuity, life-saving products is “very inelastic.”
Ford said 80% of Abbott’s expected second-half growth acceleration is expected to come from four areas: nutrition, electrophysiology, core laboratory and cancer diagnostics.
On continuous glucose monitoring, Ford said Abbott remains bullish on the market, estimating that 75 million to 80 million people globally could realistically use CGM, compared with about 15 million today. He said reimbursement expansion is the most immediate driver of adoption, and Abbott is in discussions with about a dozen countries on introducing or expanding coverage. In the U.S., he said broader type 2 diabetes coverage could unlock about 10 million Medicare beneficiaries and accelerate commercial insurance coverage, though he did not provide a specific timing forecast.
Looking beyond 2026, Ford declined to provide specific 2027 guidance but said Abbott continues to target high-single-digit top-line growth and double-digit earnings growth. He described 7% sales growth as a sustainable target for the company, supported by its mix of nutrition, diagnostics, established pharmaceuticals and medical technology businesses.
About Abbott Laboratories NYSE: ABTAbbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Abbott Laboratories Right Now?Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Abbott Laboratories oznámila, že tržby segmentu Medical Devices v 1. čtvrtletí 2025 vzrostly o 13,2 % na 5,54 miliardy USD a FreeStyle Libre přidal 13,8 % na 2,08 miliardy USD. Upravený EPS byl 1,15 USD a celoroční výhled je 5,38 až 5,58 USD.
The market still treats Abbott Laboratories (NYSE:ABT | ABT Price Prediction) like a bond proxy with a stethoscope: baby formula, branded generics, and a metronomic dividend. That framing looks increasingly stale, and the stock’s punishing drawdown has widened the gap between narrative and numbers.
Abbott is a card-carrying S&P 500 Dividend Aristocrat, riding a 54th consecutive year of dividend increases and a 410th consecutive quarterly payout of $0.63 per share. A beta of 0.607 reinforces the “sleep well at night” identity. That reputation is precisely why the transformation underneath it is being underpriced.
A New Growth Engine and a Pivot Hiding in Plain Sight Medical Devices is now the dominant engine, generating $5.54 billion in Q1 2026, up 13.2%. Inside that segment, the FreeStyle Libre continuous glucose monitor franchise cleared $2.08 billion in the quarter, growing 13.8%. CEO Robert Ford is explicit about the runway: “Our assessment of the number of people who should be on a CGM on a global basis is between 70 million and 80 million people. The market today is around 10 to 12 million people.”
Established Pharmaceuticals grew 13.2% and international sales rose 11.3%. Adjusted EPS came in at $1.15, the fourth consecutive beat, with full-year adjusted EPS guidance of $5.38 to $5.58. Abbott remains a compounder still compounding.
On March 23, 2026, Abbott closed its roughly $21 billion acquisition of Exact Sciences, launching a Cancer Diagnostics unit anchored by Cologuard and Cancerguard. Management expects approximately $3 billion of incremental sales in 2026. Ford framed the strategic logic: “About 50 million Americans are not up to date with CRC screening… Cologuard does really well here. Not only is it convenient at home, but its sensitivity at 95% is equivalent to colonoscopy.”
The Mispricing Shares closed most recently at $89.27, down 28.8% year to date and 32.1% over one year. The $116.54 analyst consensus target is below the 52-week high of $137.49, yet analysts overall still recommend buying shares. The forward P/E is 17.
_________________________________
What's Your Number...?Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
For investors weighing durable payers (our Dividend Kings research covers this cohort in depth), the disconnect between fundamentals and price action is notable.
Reframing the Legacy Drag Nutrition fell 6.0% to $2.02 billion, the piece of “old Abbott” the market fixates on. Ford has been clear that this is deliberate: “We did not reduce price uniformly; we kept it focused on products that… would demonstrate a positive volume response to reduced price.”
Nutrition volume recovery, FX, $0.20 per share of Exact Sciences dilution, China volume-based procurement, and continuous glucose monitoring competition from DexCom (NASDAQ:DXCM) are genuine. Polymarket traders currently place the probability of Q2 comparable sales growth falling within the 4% to 8% band at 44% to 45%. These are the concerns of a growth-plus-quality compounder.
This article is research commentary, not investment advice.
If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:
Answer a Few Simple Questions.
Get Matched with Vetted Advisors
Choose Your Fit
Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)
Abbott (ABT - Free Report) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +2.34%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.14 per share when it actually produced earnings of $1.15, delivering a surprise of +0.88%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $12.59 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $11.14 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have lost about 28.8% since the beginning of the year versus the S&P 500's gain of 10.6%.
What's Next for Abbott?While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.42 on $13.15 billion in revenues for the coming quarter and $5.48 on $50.42 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Perrigo (PRGO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.
This drug company is expected to post quarterly earnings of $0.39 per share in its upcoming report, which represents a year-over-year change of -31.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Perrigo's revenues are expected to be $1 billion, down 5% from the year-ago quarter.
Abbott oznámí výsledky za 2. čtvrtletí 2026 16. července; trh očekává EPS 1,28 USD a tržby 12,48 mld. USD. Akcie za poslední tři měsíce klesly o 11,4 %.
Key Takeaways Abbott is expected to report Q2 EPS of $1.28 on $12.48B in revenues, up 1.6% and 12% year over year.ABT may benefit from Core Lab, Cancer Diagnostics, cardiovascular devices and EPD, while Nutrition stays weak.ABT trades below its historical valuation despite recent share weakness ahead of its July 16 earnings report. Abbott Laboratories (ABT - Free Report) is slated to report its second-quarter 2026 results on July 16, before the opening bell.
The Zacks Consensus Estimate for the company’s second-quarter earnings per share (EPS) suggests 1.6% year-over-year growth to $1.28. The estimate has remained constant in the past 60 days. The consensus mark for second-quarter revenues currently stands at $12.48 billion, implying a 12% increase over the prior-year period.
Image Source: Zacks Investment Research
In the trailing four quarters, the company topped earnings estimates twice and broke even on two occasions, the average surprise being 0.42%.
Image Source: Zacks Investment Research
Q2 Earnings Whispers for AbbottPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Abbott has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank:The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Factors Likely to Have Shaped ABT’s Q2 PerformanceDiagnosticsWithin this segment, Abbott may have delivered mixed performance in the second quarter. Rapid and Molecular Diagnostics are likely to have continued to face reduced demand for respiratory virus testing. At the same time, steady demand for the Core Lab diagnostic tests may have been a tailwind, with strong performance across the United States, Europe and Latin America.
Following the acquisition of Exact Sciences, Abbott added the Cancer Diagnostics business, expanding into one of the fastest-growing areas of healthcare. We assume the division to have favorably impacted the quarter’s results, driven by the Cologuard colorectal cancer (CRC) test momentum and contributions from the international markets.
A positive development in the quarter was the American Cancer Society’s updated CRC screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred non-invasive screening options for adults aged 45 and older who are at average risk. This is expected to have positively boosted adoption trends and revenues.
The Zacks Consensus Estimate anticipates Diagnostics revenues to increase 41.6% year over year.
Established Pharmaceutical Products (“EPD”)The segment is expected to have maintained its growth momentum in key emerging markets, supported by favorable long-term health care, economic and demographic trends, with a broad product offering across five therapeutic areas. The biosimilars portfolio, which has expanded to include several market-leading oncology therapies, may have been a positive driver as well for the segment’s top line.
Going by the Zacks Consensus Estimate, EPD revenues are likely to grow 6.6% from the prior-period levels.
Medical DevicesAbbott’s cardiovascular businesses are expected to have been the biggest contributor to Medical Devices’ top line in the second quarter of 2026.
Electrophysiology performance may have been boosted by contributions from the Volt and TactiFlex Duo pulsed field ablation (PFA) catheters. Rhythm Management likely continued to outpace the market, driven by the Aveir leadless pacemaker. Heart Failure business results may have benefited from the Heart Assist Devices portfolio.
In Vascular, the company secured FDA clearance and CE Mark for its next-generation Ultreon 3.0 Software in the quarter, bringing coronary imaging and AI-automated insights together in one system. The enhanced coronary portfolio likely contributed positively to the quarter’s results.
In Neuromodulation, Abbott’s rechargeable spinal cord stimulation device Eterna may have continued to see strong international adoption trends.
Further, the Diabetes Care business may have regained growth momentum following the easing of temporary headwinds, including a delay in the international tender renewal process and a challenging prior-period comparison.
The Zacks Consensus Estimate expects Medical Devices revenues to increase 8.5% year over year.
NutritionThe segment is expected to have faced revenue pressure in the second quarter, as Abbott continues to transition toward a more sustainable balance between price and volume-driven growth. Sales volumes across both pediatric and adult nutritional product portfolios in the United States and internationally may have been lower. Although management reported early progress from these strategic actions in the previous quarter, it is yet to fully materialize.
The Zacks Consensus Estimate indicates Nutrition revenues will decline 4.3% year over year.
Abbott’s Peers Reporting Next WeekQuest Diagnostics (DGX - Free Report) is set to report second-quarter 2026 results on July 23, before the opening bell. The company’s Diagnostic Information Services segment is expected to have maintained its growth momentum, supported by organic growth across the physician, hospital and consumer channels. Contributions from recent acquisitions may have been a key driver. Productivity gains from the company’s automation and AI initiatives are likely to have favored the bottom line.
Thermo Fisher (TMO - Free Report) is also slated to report its 2026 second-quarter results before the market opens on July 23. Strength in the bioproduction and clinical research business, and the research and safety market channel may have supported the pharma and biotech end-market performance. Several recently launched high-impact innovations may have lifted revenues. The continued adoption of accelerated drug development offering is likely to have translated to share gain in its clinical research business.
ABT’s Price Performance & ValuationIn the three months ended June 30, Abbott shares have dropped 11.4%, underperforming the industry’s 10.1% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott trades at a forward five-year Price/Earnings (P/E) of 15.93X, lower than its median of 23.28X and 16.21X industry average.
Image Source: Zacks Investment Research
EndnoteAbbott is well-positioned to benefit from strength across several of its key businesses in the second quarter of 2026, including Core Lab Diagnostics, EPD and Electrophysiology. The newly added Cancer Diagnostics portfolio is also expected to have contributed. Nutrition may have continued to navigate the near-term impact of its pricing and volume transition, with the benefits of these strategic actions expected to build over time. In the trailing four quarters, Abbott beat earnings estimates twice and came in line on two occasions.
Despite its recent underperformance, ABT is trading at a relatively cheaper valuation. Given Abbott’s strong fundamentals and diversified growth drivers, we believe existing shareholders should continue to retain their positions to enjoy long-term gains.
Abbott klesl o 1,5 % na 92,71 USD, zatímco S&P 500 vzrostl o 1,18 %. Firma zveřejní výsledky za čtvrtletí 16. července; odhad EPS je 1,28 USD a tržby 12,53 mld. USD.
Abbott (ABT - Free Report) closed the most recent trading day at $92.71, moving -1.5% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.18%. Meanwhile, the Dow gained 0.59%, and the Nasdaq, a tech-heavy index, added 2.07%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 9.95% outpaced the Medical sector's gain of 7.96% and the S&P 500's loss of 2.9%.
Analysts and investors alike will be keeping a close eye on the performance of Abbott in its upcoming earnings disclosure. The company's earnings report is set to go public on July 16, 2026. The company's earnings per share (EPS) are projected to be $1.28, reflecting a 1.59% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $12.53 billion, indicating a 12.43% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.48 per share and revenue of $50.49 billion, which would represent changes of +6.41% and +13.9%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Abbott presently features a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 17.18 right now. This valuation marks a discount compared to its industry average Forward P/E of 18.95.
Meanwhile, ABT's PEG ratio is currently 1.62. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 1.65 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 169, finds itself in the bottom 31% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Abbott očekává, že tržby z CGM se ve 2. čtvrtletí vrátí k dvoucifernému růstu po odeznění dočasných překážek. Získal také označení CE pro Libre Duo a Libre Duo 10 Day s duálním snímáním glukózy a ketonů.
Key Takeaways ABT expects CGM sales to return to double-digit growth after temporary second-quarter headwinds ease.ABT secured CE Mark for Libre Duo and Libre Duo 10 Day with dual glucose and ketone sensing.Abbott sees broader Volt and TactiFlex Duo PFA rollout boosting Electrophysiology growth acceleration. Abbott (ABT - Free Report) generates the largest share of its revenues from the Medical Devices unit. Sales in 2025 reached $21.39 billion, up 11.9% from the prior-year levels. That strength continued into the first quarter of 2026, with revenues rising 8.5% on a comparable basis, led by the strong performance of its cardiovascular device businesses. Abbott believes its investments in the foundational businesses like Rhythm Management and Vascular continue to pay off, even as the traditionally higher-growth segments draw most of the attention. With the July 16 second-quarter 2026 earnings approaching, several recent developments and pipeline progress are expected to help sustain this momentum, with some expected to have a greater impact as the year progresses and beyond.
In Diabetes Care, continuous glucose monitoring (CGM) sales will likely return to the double-digit growth in the second quarter, after temporary headwinds from delays in the renewal process related to an international tender and difficult prior-year comparisons. Abbott expanded the portfolio by recently securing CE Mark for Libre Duo and Libre Duo 10 Day, the world's first-ever dual glucose-ketone sensing technology designed to continuously measure glucose and ketone levels every minute.
Further, Rhythm Management could continue outperforming the broader market, supported by the strong adoption of the AVEIR leadless pacemaker. Together with ongoing investments in conduction system pacing and other novel technologies, Abbott believes the $10 billion Rhythm Management market offers substantial room to expand share and drive sustainable long-term growth.
Meanwhile, the Heart Assist Devices portfolio for the treatment of chronic and temporary conditions is expected to remain a strong contributor to the Heart Failure business. In Electrphysiology, Abbott expects growth to accelerate as it broadens the rollout of Volt and TactiFlex Duo Pulsed Field Ablation (PFA) catheters.
ABT’s Peer Activity in FocusMedtronic (MDT - Free Report) recently completed the acquisition of Scientia Vascular, a privately held medical device company in Salt Lake City. The deal is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition. The addition of Scientia's access technologies is expected to boost Medtronic’s Neuroscience Portfolio.Financially, the deal is expected to be minimally dilutive to the company’s adjusted EPS in FY 2027 and accretive thereafter.
Quest Diagnostics’ (DGX - Free Report) Haystack MRD test has been approved by the New York State Department of Health's Clinical Laboratory Evaluation Program. The circulating tumor DNA liquid biopsy test is meant for use in identifying residual or recurring disease in patients with a range of solid tumor cancers. Quest Diagnostics developed the test under CLIA regulations and has been available for clinician ordering since late 2024 in 49 states and the District of Columbia.
ABT’s Price Performance, Valuation & EstimatesOver the past year, ABT shares have plunged 30.8% compared with the industry’s 28% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott is trading at a forward, five-year Price/Sales (P/S) of 3.11X, lower than its 4.63X median but above its industry average of 2.16X.
Image Source: Zacks Investment Research
Here’s how consensus estimates for Abbott’s 2026 and 2027 earnings have been shaping up.
Image Source: Zacks Investment Research
Abbott currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ministerstvo spravedlnosti USA ukončilo trestní vyšetřování společnosti Abbott Laboratories kvůli závodu na výrobu kojenecké výživy a namísto toho zvažuje civilní sankce. Firma v roce 2022 stáhla produkty z trhu a uzavřela michiganský závod po nálezu potenciálně smrtelné bakterie.
Abbott's milk powder products are displayed on a shelf at a supermarket in Beijing August 7, 2013. Abbott Laboratories has agreed to pay a fine amounting to around $12 million, a spokeswoman... Purchase Licensing Rights, opens new tab Read more
CompaniesJune 28 (Reuters) - The U.S. Justice Department closed a criminal probe into Abbott Laboratories (ABT.N), opens new tab over its handling of a baby formula plant linked to potentially deadly bacteria and infant deaths, opting instead for civil penalties, the Wall Street Journal reported on Sunday.
Reuters could not immediately verify the report. The U.S. Department of Justice and Abbott Laboratories did not immediately respond to a request for comment outside business hours.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Abbott initiated a recall of its infant formula products and closed its Michigan plant in 2022 after investigators found traces of a potentially deadly bacteria at that plant. The recall and the plant closure worsened a national shortage of baby formula that had begun with pandemic supply chain issues.
Abbott had said at the time that there was no evidence linking its formulas to these illnesses. No unopened, distributed Abbott infant formulas have tested positive for the bacteria that sickened the babies, a company spokesman told the WSJ.
Some prosecutors believed they had evidence to criminally charge the company, but top decision makers closed the probe, according to the WSJ report. Instead, they opted for the lighter option of clawing back money the company earned from selling formula through federally funded nutrition programs, the report added.
“Ensuring the safety of our nation’s food supply is a top priority for the Trump administration; however, this Department of Justice does not believe in regulation by prosecution,” a spokeswoman for the DOJ told WSJ.
Prosecutors had been considering a misdemeanor charge against Abbott for violating the federal Food, Drug and Cosmetic Act and a separate count for misleading the government before dropping the case, the report said, and added that prosecutors were also considering charging at least one individual.
Reporting by Akanksha Khushi in Bengaluru; Editing by Rashmi Aich
Our Standards: The Thomson Reuters Trust Principles., opens new tab
DexCom potvrdil výhled růstu tržeb na rok 2026 o 11 % až 13 % a dál rozšiřuje adopci CGM díky novým produktům a širšímu pokrytí. Abbott naopak čelí slabosti diagnostiky, nejistotě v Číně a ředění EPS po akvizici Exact Sciences.
Key Takeaways Abbott faces Diagnostics weakness, China uncertainty and EPS dilution from the Exact Sciences deal.DXCM is expanding CGM adoption through new products, broader coverage and global market growth.DXCM reiterated 2026 revenue growth guidance of 11%-13% and expects wider G7 15 Day adoption. With the rising prevalence of diabetes worldwide, the demand for more efficient and real-time glucose monitoring solutions has intensified. Abbott (ABT - Free Report) and DexCom (DXCM - Free Report) are among the leading players in the continuous glucose monitoring (CGM) device market, valued at $13.4 billion in 2025 by Grand View Research.
Healthcare giant Abbott’s businesses span cardiovascular care, diagnostic testing, nutrition, pain and movement disorders, with Diabetes Care being a consistent top-line driver for the past several quarters. On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who struggle with hypoglycemia.
Here’s a closer look at both companies to determine which stock offers the more compelling investment opportunity today.
The Case for Abbott
Abbott’s flagship, sensor-based CGM system, FreeStyle Libre, has quickly established global leadership across both Type 1 and Type 2 diabetes. CGM sales reached $2 billion in the first quarter of 2026, up 7.5% year over year, though growth was affected by a delay in an international tender renewal and a difficult prior-year comparison tied to shelf restocking dynamics. CGM growth is forecasted to return to double-digits in the second quarter.
Abbott’s CEO also remains bullish on the long-term CGM opportunity, estimating that 70-80 million people globally should be using CGMs compared with the current market of roughly 10-12 million users. Recently, the company secured CE Mark for the first-ever dual glucose-ketone sensing technology for people with diabetes, branded as Libre Duo and Libre Duo 10 Day. The systems continuously measure glucose and ketone levels every minute and will integrate with the Libre digital health ecosystem.
Beyond Diabetes Care, Abbott’s Core Lab Diagnostics business is seeing robust demand across the United States, Europe and Latin America. However, Core Lab trends were flat in China, with the company continuing to expect a weaker market for the full year despite lapping prior pricing actions.
The March 2026 acquisition of Exact Sciences added a Cancer Diagnostics business, expanding presence in one of the fastest-growing areas of healthcare. Even so, the deal introduces a $0.20 dilution to the 2026 adjusted EPS guidance of $5.38 to $5.58.
Abbott’s Rapid and Molecular Diagnostics business suffered from lower demand for respiratory virus testing due to a much weaker respiratory season compared to last year. Management is taking a cautious view and is not assuming the shortfall will recover later in the year. The Established Pharmaceuticals Division benefits from branded generics positions in faster-growing geographies. Abbott is focused on restoring a healthier balance between price and volume over time in Nutrition, while its Medical Devices segment is gaining from scale advantages and new product cycles across the franchises.
Take a look at how analysts are projecting Abbott’s bottom line.
Image Source: Zacks Investment Research
The Case for DexCom
DexCom is benefitting from broader access to its CGM product portfolio, continued active base growth and new product launches. The company has partnered with several insulin delivery systems manufacturers to integrate its CGM products, with more than one million CGM users now connected to an automated insulin delivery (AID) system worldwide.
Internationally, DexCom’s 2026 first-quarter growth was widespread across core markets, with notable strong performance in countries such as France and Canada, where access has recently expanded. Management outlined a targeted international strategy aimed at gaining share through reimbursement progress and a portfolio tailored to local channels, including DexCom One+ in Europe.
In the quarter, DexCom made an expanded rollout of the G7 15 Day sensor across all U.S. channels. The platform is now available with all U.S. pump partners, helping minimize friction for AID users who upgrade within the installed base. DexCom expects nearly 50% conversion of the U.S. base to the 15-day sensor by year-end 2026, with an international launch expected to begin in the second half of the year. The company also introduced its next-generation G8 roadmap, designed to deliver a step-change improvement in glucose performance with a smaller form factor and self-adapting sensor.
DexCom continues to build out its software ecosystem, adding engagement tools for Stelo, including enhanced Smart Meal Logging features, and it has been expanding provider-facing capabilities through Direct EHR Integration. More than 320 health systems have already integrated or are in the process of onboarding this capability across the United States and international markets.
The company also continues to expand insurance coverage for its CGM sensors, particularly among Type 2 diabetes patients. The three largest U.S. Pharmacy Benefit Managers now cover DexCom CGM for all people with diabetes, including those with type 2 not using insulin.
ABT also reiterated its 2026 revenue guidance, calling for 11% to 13% growth over 2025 levels. Take a look below at how the company’s earnings estimates are shaping up.
Image Source: Zacks Investment Research
ABT & DXCM: Price Performance and Valuation
Year to date, ABT shares have declined 25.6%, whereas DexCom shares have climbed 4.1%.
Image Source: Zacks Investment Research
Abbott is trading at a forward, five-year Price/Sales (P/S) of 2.99X, below its median of 4.63X. Meanwhile, DXCM sits with a five-year P/S of 4.88X, also lower than its median of 9.93X.
Image Source: Zacks Investment Research
Conclusion
Both companies are poised to benefit from the long-term growth trends of the CGM market. However, Abbott continues to face respiratory testing volatility in Diagnostics, dilution risk following the Exact Sciences acquisition and ongoing uncertainty in China. DexCom is gaining from elevated CGM demand worldwide, new product launches and expanding coverage for its sensors.
While DexCom trades at a premium to Abbott, it remains well below its historical median. The stock has also delivered stronger YTD performance relative to Abbott. Coupled with positive earnings estimate revisions, existing DXCM holders may find it prudent to stay invested to enjoy growth prospects. Meanwhile, those holding ABT stock may find it wise to sell for now until the short-term operating visibility improves.
DXCM carries a Zacks Rank #3 (Hold), while ABT has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring.
Pillar One: Durability Built Into the Business Model Abbott’s revenue flows from four distinct segments spanning multiple geographies and therapeutic areas, and the latest quarter shows why that matters. In Q1 2026, Medical Devices delivered $5.54 billion (+13.2% YoY), Diagnostics added $2.18 billion (+6.1%), Established Pharmaceuticals grew +13.2% in emerging markets, and Nutrition shrank 6.0%. Three segments offset the weak one, and total revenue still grew 7.8% to $11.16 billion, exactly the four-headed structure that absorbs localized blows while sustaining cash flow.
The moat keeps widening. The $21 billion Exact Sciences acquisition closed March 23, 2026, adding Cologuard and Cancerguard to the diagnostics arsenal. FreeStyle Libre, the continuous glucose monitor franchise, generated $2.08 billion (+13.8% YoY) in the first quarter alone, a consumable razor-and-blade business that, as global diabetes rates climb, creates an exceptionally sticky customer relationship.
Pillar Two: Income You Can Set and Forget Abbott just paid its 409th consecutive quarterly dividend. The quarterly payout has climbed from $0.14 in 2013 to $0.63 in early 2026, with the most recent declaration set at $0.740243 per share, payable August 17, 2026. The trailing dividend currently yields 2.76%, modest at the surface, meaningful when paired with a multi-decade compounding curve. Backing the payout: trailing twelve-month revenue of $45.1 billion, a 13.9% profit margin, and a forward P/E of 16.
Pillar Three: Why It Survives Cycles Healthcare demand is largely non-discretionary. Glucose monitors, heart valves, lab diagnostics, and infant nutrition do not get postponed when GDP wobbles. The numbers reflect that defensive profile: a beta of 0.62, 82.67% institutional ownership, and operations across 160-plus countries. Management is guiding full-year 2026 to comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, even after absorbing $0.20 of Exact Sciences dilution.
Where It Underperforms In low-rate, high-growth bull markets, a defensive aristocrat with a beta of 0.62 will trail high-beta technology and small caps. Abbott is also down 30.67% over the past year as the market rotated toward speculative names. That lag does not change the forever thesis. Owners of a Dividend Aristocrat are paid in compounding payouts and capital preservation, not in narrative-driven rallies, and the same low-volatility profile that caps upside in bull runs is what protects capital when the rotation reverses.
At a price of $90.53, well below the analyst target of $116.54 and the 200-day moving average of $113.41, the current setup combines a meaningful yield, a 54-year dividend-growth track record, and exposure to chronic-disease secular growth. The setup favors long-duration ownership over short-term trading.
ALZpath uzavřela globální licenční dohodu s Abbott Laboratories na vývoj krevního testu na Alzheimerovu chorobu. Abbott začlení její protilátku do testu pro systémy Alinity.
A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Centre at the Department of... Purchase Licensing Rights, opens new tab Read more
CompaniesJune 24 (Reuters) - ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories (ABT.N), opens new tab to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use diagnostic options for the brain-wasting disease.
Here are some more details:
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
Abbott will incorporate ALZpath's antibody into a test designed to run on its Alinity laboratory systems.
Blood tests offer an alternative to diagnosing Alzheimer's, which has been traditionally diagnosed through expensive and invasive PET imaging and cerebrospinal fluid analysis.
The California-based company has previously partnered with Roche, Beckman Coulter and Siemens Healthineers.
ALZpath CEO Mike Banville told Reuters exclusively that the company has opted to partner with firms through licensing agreements, as this approach enables it to reach patients more quickly with its blood-based test.
"With Abbott on board... we will now have 80% of the in-vitro diagnostic market, roughly, using the ALZpath antibody," Banville added.
The test targets pTau217, a blood marker linked to changes seen in Alzheimer's disease.
ALZpath scientific adviser Henrik Zetterberg said that pTau217 is a "bit of a revolution in detecting Alzheimer's disease early." The marker can reveal changes years before dementia sets in, and help assess patients with memory symptoms.
Regulatory progress is expected in the coming months, with U.S. approvals for some partners anticipated in the back half of the year, Banville said.
Blood tests, including one developed by Japan-based Fujirebio, have already received U.S. regulatory clearance, opens new tab for Alzheimer's diagnosis.
ALZpath did not disclose the financial terms of the deal with Abbott, but Banville said the partnership follows a royalty-based licensing model.
Reporting by Sahil Pandey in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Akcie Abbott klesly o 29,4 % od začátku roku kvůli nižší poptávce po respiračních testech, nejistotě v Číně a vyšším nákladům, přičemž společnost očekává růst tržeb v roce 2026 o 6,5–7,5 % a upravený EPS ve výši $5.38-$5.58.
Key Takeaways Abbott shares are down 29.4% YTD, lagging its industry, sector and selected peers.Abbott cited weaker respiratory testing demand, China uncertainty and higher costs as challenges.Abbott expects 2026 sales growth of 6.5%-7.5% and adjusted EPS of $5.38-$5.58. Abbott (ABT - Free Report) has struggled in the market this year despite a series of regulatory, clinical and business developments. Shares have declined 29.4% year to date, underperforming the industry’s 24.1% drop and the Medical sector’s 5.8% plunge, while the S&P 500 composite has gained 9.7%. ABT closed the last trading session at $88.41, roughly 36.4% below its 52-week high of $139.06 and only 8% above its 52-week low of $81.97.
The stock’s performance has also lagged some notable peers. Shares of Becton, Dickinson and Company (BDX - Free Report) , or BD, have declined 25.8% this year, while Labcorp (LH - Free Report) has risen 2%. Since separating its Biosciences and Diagnostic Solutions business and its combination with Waters, BD has sharpened its focus as a pure-play MedTech company, which appears to be gaining traction. Labcorp, too, continues to benefit from its ongoing momentum in key specialty testing areas and strengthens its position as a top partner for health systems and regional local laboratories.
Image Source: Zacks Investment Research
From a technical standpoint, ABT is currently trading below its 50-day and 200-day moving averages, suggesting that shares could remain under pressure.
Image Source: Zacks Investment Research
Illinois-based Abbott is a major player in the healthcare space with several growth drivers across its diversified portfolio. The Established Pharmaceuticals Division is a steady contributor to the revenue base, supported by branded generics positions in faster-growing geographies. Within the Nutrition segment, the company is working through a transition that is intended to restore a healthier balance between price and volume over time. Medical Devices continues to benefit from scale advantages and new product cycles across Cardiovascular and Diabetes units. Still, several challenges continue to weigh on the near-term outlook.
What’s Holding Back Abbott?Respiratory Testing Demand Remains Volatile: Abbott’s Diagnostics results still face mixed swings as respiratory virus testing continues to normalize from prior years. In the first quarter of 2026, Rapid and Molecular Diagnostics declined 9.6% on a comparable basis, reflecting lower demand for respiratory virus tests versus the prior-year season. While Core Laboratory grew 3.3% on a comparable basis and Cancer Diagnostics added growth following the Exact Sciences acquisition, the segment’s near-term reported profile can remain uneven as respiratory seasons fluctuate and pandemic-related comparisons fade.
Macro-Driven Cost Pressures: Abbott continues to operate against an uncertain macroeconomic backdrop that can influence input costs and demand patterns across categories. In the first quarter of 2026, selling, general and administrative expenses increased 22.2% year over year, partly reflecting acquisition-related items, and the company continues to incur incremental costs tied to European MDR and IVDR compliance. If pricing, mix or volumes weaken in areas such as Nutrition, Abbott may have less flexibility to offset these costs, which could weigh on profitability even with ongoing cost actions.
China Policy Uncertainty Lingers:China remains a source of uncertainty, particularly within Diagnostics, where government procurement policies have affected pricing and volumes. Management indicated that Core Laboratory trends in China were flat in the first quarter of 2026 and expects China to remain down for the full year, even as the company laps parts of prior pricing actions. Future procurement rounds and policy shifts can still alter demand visibility and create additional volatility versus Abbott’s more stable geographies.
Abbott’s FY 2026 GuidanceWith the Exact Sciences acquisition now complete, Abbott expects full-year 2026 sales growth outlook 6.5% to 7.5% on both a reported and comparable basis. The company also updated its adjusted earnings per share (EPS) guidance to $5.38-$5.58. The new midpoint of $5.48 reflects roughly $0.20 of dilution tied to the acquisition.
At present, the Zacks Consensus Estimate expects Abbott’s earnings to rise 6.4% in 2026 and another 10.5% in 2027. However, estimates have seen downward revisions over the past 90 days.
Image Source: Zacks Investment Research
The consensus mark for Abbott’s revenues calls for 13.9% and 8.9% growth in 2026 and 2027, respectively.
ABT’s Valuation SnapshotWith a Value Score of C, Abbott is currently trading at a forward, five-year, Price/Sales of 2.93X, representing a premium to the industry average of 2.05X.
Image Source: Zacks Investment Research
ABT also has a higher sales multiple compared to Labcorp’s 1.39X five-year P/S, as well as Becton, Dickinson’s P/S of 2.02X.
ConclusionAbbott’s sharp year-to-date decline reflects the impact of a weaker-than-expected respiratory season on its quarterly results, dilution risk from the Exact Sciences acquisition and ongoing macroeconomic pressures, among others. In China, management continues to maintain a cautious outlook despite flat Core Laboratory trends in the first quarter. The company’s technical indicators also point to continued weakness. Analysts have revised Abbott’s fiscal-year 2026 and 2027 estimates lower in recent months. Given its elevated valuation relative to industry and peers, existing ABT holders may want to exit their positions until visibility into near-term performance improves.
Abbott currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott (ABT - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this maker of infant formula, medical devices and drugs have returned +0.5%, compared to the Zacks S&P 500 composite's +0.1% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has lost 3.7%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Abbott is expected to post earnings of $1.28 per share, indicating a change of +1.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $5.48 for the current fiscal year indicates a year-over-year change of +6.4%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $6.05 indicates a change of +10.5% from what Abbott is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Abbott.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Abbott, the consensus sales estimate of $12.53 billion for the current quarter points to a year-over-year change of +12.4%. The $50.49 billion and $55.01 billion estimates for the current and next fiscal years indicate changes of +13.9% and +9%, respectively.
Last Reported Results and Surprise HistoryAbbott reported revenues of $11.16 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $1.15 for the same period compares with $1.09 a year ago.
Compared to the Zacks Consensus Estimate of $11.02 billion, the reported revenues represent a surprise of +1.31%. The EPS surprise was +0.88%.
Over the last four quarters, Abbott surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
